Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Napo Pharmaceuticals Inc. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 2 distinct examiners, providing the company with multiple perspectives on their patent applications. However, both actions are housed within 1 distinct art unit, which suggests that the technical focus of the 2 pending office actions is relatively narrow.
The busiest examiner, HUI, SAN MING R, is responsible for 1 busiest examiner pending action. Because the total number of actions is 2 and the busiest examiner pending count is 1, the workload is shared between the 2 distinct examiners. This allows the practitioner to compare how different individuals within the same 1 distinct art unit interpret the Biotechnology & Pharmaceuticals subject matter. The presence of 2 distinct examiners reduces the risk associated with a single examiner's review, even though the 1 distinct art unit remains a constant factor in the prosecution of these 2 pending office actions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Double-patenting only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUI, SAN MING R | 1 | 59.5% | +20.1% |
| HASTINGS, ALISON AZAR | 1 | 63.5% | +40.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18520464 | METHODS AND COMPOSITIONS FOR TREATING CONGENITAL DIARRHEA DISORDER | HUI, SAN MING R | 119d overdue |
| 17866453 | METHODS AND COMPOSITIONS FOR TREATING CHEMOTHERAPY-INDUCED DIARRHEA | HASTINGS, ALISON AZAR | — |
| Art Unit | Apps |
|---|---|
| 1627 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18520464 | METHODS AND COMPOSITIONS FOR TREATING CONGENITAL DIARRHEA DISORDER | HUI, SAN MING R | 1627 | DP | Non-Final OA | 119d overdue | Pending | Nov 27, 2023 |
| 17866453 | METHODS AND COMPOSITIONS FOR TREATING CHEMOTHERAPY-INDUCED DIARRHEA | HASTINGS, ALISON AZAR | 1627 | §112 | Non-Final OA | — | Pending | Jul 15, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial